Department of Pharmacy
|Vice Dean||M. Miura|
|Vice Dean||T. Funatsu|
|Member of the Education and Research Council||T. Funatsu|
(2018.4.20Updated)*:Medicine science department chair
*:Pharmacy department chair
Laboratory of Chemistry and Biologyhttp://www.f.u-tokyo.ac.jp/~taisha/en/
Prof. Y. Urano★
Assoc. Prof. K. Hanaoka
Assist. Prof. T. Ueno
Assist. Prof. T. Komatsu
We create a novel research ﬁeld termed "Chemical Biology" so as to promote development of life sciences and medicine.Research Topics
- Development and application of functional contrast agents of magnetic resonance imaging (MRI)
- Theoretical design and development of ﬂuorescent probes for living cells, and their in vivo application for clinical use
- Rational design and development of novel ﬂuorophores and their application for ﬂuorescent probes
- Research on drug discovery: Development of chemical compounds that control disease-related proteins, and development of high-quality screening systems
Our laboratory conducts research on the analysis and modification of dynamic living systems, using chemistry as a powerful tool. In particular, we address two research themes: bioimaging and drug discovery. With respect to the ﬁrst topic, one of the important goals in modern life sciences is to elucidate the dynamic behaviors of biomolecules in situ in the living cells/organisms. Because spatiotemporal information of molecules is lost once the cells/tissues are homogenized for subsequent analysis, it is important to develop functional bioimaging probes that can be used in the systems. So far, our laboratory has developed bioimaging probes based on the design strategies we established by ourselves. The other goal of our group is to achieve university-driven drug discovery using a chemical library containing over 200,000 compounds, with our original screening systems. We are searching for novel lead compounds to cure diseases that are too challenging to address for private companies. The above-described two areas of research have attracted enormous attention in recent years under the name of "Chemical Biology", and we believe that they will open up new horizons in life sciences.
Laboratory of Protein Structural Biologyhttp://www.f.u-tokyo.ac.jp/~kouzou/index_e.html
Prof. T. Shimizu
Assoc. Prof. U. Ohto
Assist. Prof. S. Toma
Determining three-dimensional structures of proteins and nucleic acids, and elucidating their functions in living cellsResearch Topics
- Structural biology of proteins and nucleic acids using X-ray crystallography and small angle X-ray scattering
- Structure and function relationship of proteins and nucleic acids
- Structures of nuclear proteins and their complexes
- Structures of proteins in homologous recombination
- Structures of immune-system and membrane proteins, and their complexes
Structural biology elucidates three-dimensional structures of proteins and nucleic acids and also biological phenomena such as their activities, functions, properties, interactions, and roles in living cells. In the elucidation of three-dimensional structures, X-ray crystallography is extensively used since this method provides us with detailed structural information on the biological functions and roles. We also take an interdisciplinary approach, combining methods of biophysics, biochemistry, molecular biology, genetic and protein engineering, and small angle X-ray scattering. With this structural biological approach, we can obtain the information on three dimensional structures that are required for drug design and discovery.
Based on this foundation of the research and the objectives, we carry out structural biological researches into nuclear proteins, proteins in homologous recombination and immune-system proteins.
Three dimensional structure of nuclear protein, nucleomethylin
Three dimensional structure of immune-system protein, MD-2 in complex with lipid
Laboratory of Immunology and Microbiologyhttp://www.f.u-tokyo.ac.jp/~bisei/
Prof. S. Hori
Assoc. Prof. C. Kaito
Assist. Prof. A. Nakajima
Assist. Prof. R. Murakami
Understanding the principles of immunological tolerance and homeostasisResearch Topics
- Mechanisms of immunological tolerance and homeostasis
- Mechanisms of regulatory T cell development and function
- Molecular mechanism of bacterial virulence
Disintegration of immunological “self” underlies a variety of diseases
Foxp3-expressing regulatory T (Treg) cells are indispensable for immunological tolerance and homeostasis
Laboratory of Bioorganic Chemistry (Institute for Quantitative Biosciences)http://www.iam.u-tokyo.ac.jp/chem/IMCB-8ken-HP/Index.html
Prof. Y. Hashimoto
Assoc. Prof. M. Ishikawa
Lecturer S. Fujii
Discovery and production of bioresponse modiﬁers directed toward an understanding of life phenomenaResearch Topics
- Discovery and production of molecules that control the spatio-temporally dependent expression and function of proteins
- Medicinal chemistry of nuclear receptor ligands
- Design and synthesis of bioresponse modiﬁers that control the topology and dynamism of proteins
- Developing new methods of drug discovery, using the multifunctional thalidomide as a template
The aims of this laboratory are to discover and produce new bioresponse modiﬁers based on medicinal and synthetic organic chemistry, and to use them to gain an understanding of life phenomena.
Many life phenomena are controlled by the expression, localization, and degradation of proteins. Thus far, research on chemical control of the expression of proteins has succeeded in discovering and producing various nuclear receptor ligands.
At the same time, functional molecules that regulate life phenomena through modiﬁcation of proteolysis have been designed and produced. By a method diﬀering from siRNA, it has become possible to destroy target proteins at any time, and this is expected to serve as a new technique for the functional analysis of proteins within cells.
In addition, we are designing and synthesizing molecules that control the folding process of proteins. These are compounds that control dynamic structure‒based function of proteins, and they will open up new domains in medicinal chemistry of bioresponse modiﬁers. We are also producing bioresponse modifiers using multifunctional thalidomide as a drug discovery template.
Laboratory of Molecular Pharmacokineticshttp://www.f.u-tokyo.ac.jp/~molpk/en/index.html
Prof. H. Kusuhara
Lecturer K. Maeda
Assist. Prof. H. Hayashi
Assist. Prof. T. Mizuno
Elucidation of the mechanisms determining pharmacokinetic properties of drugs that contributes to drug design, and safe and eﬀective utilization of drugsResearch Topics
- Prediction of pharmacokinetic properties and responses of drugs based on in vitro experiments: analysis of the eﬀect of genetic polymorphisms and drug-drug interactions
- Elucidation of transporters determining the elimination pathway of drugs, and drug transport systems at the blood-brain barrier
- Elucidation of mechanisms for the membrane traﬃcking of transporters
- Development of transporter-based drug delivery systems (DDS)
- Elucidation of mechanisms of drug-induced toxicity
- Elucidation of genetic and epigenetic regulation of drug transporters
Pharmacological and adverse eﬀects of drugs depend on their pharmacokinetic properties, which determine their exposure to the targets. Our laboratory aims to establish methods for quantitative and theoretical prediction of pharmacokinetic properties of new chemical entities in humans based on the molecular mechanisms. In particular, we investigate the impact of transporters on the elimination of drugs from the liver and kidney, the distribution of drugs into their target organs e.g., the brain, and drug absorption in the small intestine, in order to develop drug screening systems and to elucidate the mechanisms of drug-drug interaction, and interindividual variation in pharmacokinetics of drugs. We have also started research on the regulation of membrane traﬃcking of the transporters using low molecular weight compounds to cure transporter related-diseases. Research achievements in this laboratory contribute to predicting and evaluating rational pharmacokinetic properties in drug development, drug review and regulation, and in clinical use, and to developing medical therapy for transporter related-diseases.
Laboratory of Chemical Pharmacologyhttp://www.yakusaku.jp/home_e.htm
Prof. Y. Ikegaya
Assoc. Prof. R. Koyama
Assist. Prof. T. Sasaki
Assist. Prof. A. Nakashima
Pharmacological approach toward the brain: from molecule to animalResearch Topics
- Study on neuronal networks involved in learning and emotion using neuronal activity genetic markers
- Study on brain network operation using functional imaging of multicellular activity
- Studying on neuronal network formation during development
Pharmacology includes two aspects: 1) to analyze the biological action of drugs and 2) to search the strategies for developing treatments for diseases. We conduct our pharmacological research by taking advantage of state-of-the-art technologies and a wide range of knowledge from molecule to animal.
We focus on the roles of the cerebral limbic system and cerebral cortex, in particular, the hippocampus and amygdala, which are involved in learning, memory, and emotion.
Our experimental techniques cover from genetics, biochemistry, and cell biology to electrophysiology, histochemistry, and behavioral pharmacology. Recent technical advances have allowed us to investigate the neuronal network dynamics on far larger scales than hitherto. Functional multineuron calcium imaging reveals the dynamics of network activity with single cell/synapse resolution (Upper Figure), through which we elucidate the structural and functional relationship that generates spatiotemporally organized spike patterns. We also address the mechanisms of learning and memory using in situ mapping learning-relevant neuronal circuits with immediate early genes with cellular and temporal resolution (Lower Figure). We believe that these novel approaches open up a new avenue for our mesoscopic understandings of network function and malfunction associated with depression, stress-relevant disease, and epilepsy.
Laboratory of Neuropathology and Neurosciencehttp://www.f.u-tokyo.ac.jp/~neuropsc/
Prof. T. Tomita
Visiting Prof. S. Torii
Assist. Prof. Y. Hori
Assist. Prof. S. Takatori
Assist. Prof. A. Tarutani
From understanding the molecular pathogenesis of neurodegerative and psychiatric diseases to development of therapeutics and novel basic scienceResearch Topics
- Understanding the molecular mechanisms of intramembrane proteolysis by γ-secretase
- Research on Aβ metabolism (production, secretion and clearance) and its regulatory mechanisms
- Elucidation of pathophysiological functions of risk factors for Alzheimer diseases
- Molecular mechanisms of aberrant vesicular trafficking and diseases
- Biological and pathological roles of synaptic adhesion molecule and its metabolism
- Understanding the cellular pathology of glial cells towards development of glia-targeting drugs
- Elucidation of the molecular pathomechanisms of Parkinson disease
Aim of our laboratory is that understanding the molecular pathogenesis of neurodegenerative and psychiatric diseases to develop novel approaches to therapeutic, prevention and diagnosis. Also, we are pursuing novel basic science by understanding the molecular basis of diseases. Especially, we are studying Alzheimer disease, autism spectrum disorder and schizophrenia to identify the pathological mechanisms and therapeutic targets of these diseases at molecular levels. To understand the disease condition, we have to realize the basic mechanisms of cells and living organisms, and vice versa. We believe that this disorder-to-normal cycle in research is a basis of modern disease and basic biology, and bolsters both scientific areas by novel knowledge and technology. From this standpoint, we proceed disease-oriented molecular and cellular research in a multidisciplinary manner by mutual collaborations with organic chemists, structural biologists, physicians and pharmaceutical companies.
Aβ metabolism in the pathogenesis of Alzheimer disease
Pathological analysis of genetic protective factor for Alzheimer disease in vivo
Laboratory of Clinical Pharmacokinetics (The University of Tokyo Hospital)http://plaza.umin.ac.jp/~todaiyak/en_index.php
Prof. H. Suzuki
Lecturer T. Takada
Lecturer M. Honma
Systems-pharmacological studies for drug development in the next-generationResearch Topics
- Therapies for lifestyle-related diseases based on the comprehensive understanding of molecular mechanisms that control the transport of endogenous small molecules
- Therapies for bone metabolism diseases based on the comprehensive understanding of the dynamic control mechanisms of signal molecules involved in bone resorption and formation
- Quantitative understanding of the pharmacological and toxicological eﬀects of molecular targeted anti-cancer drugs to establish clinical applications and new drug discovery techniques
- Large-scale omics analysis to establish methods of preventing and treating adverse drug reactions based on the quantitative understanding of underlying molecular mechanisms
- Clinical pharmacokinetics based on detailed quantiﬁcation of related molecular functions
It has been recognized very well that we need to describe / predict the functions of cells, tissues and organisms from the function of each constituent molecule in a quantitative manner in order to understand the life activities. Although we have used such approach in analyzing and predicting the drug disposition in humans, it is quite important for us to expand the concept to the analysis of pharmacological / toxicological actions of drugs in humans. We are using such "systems-pharmacological" methods to solve many kinds of problems that remain great challenges in drug discovery, such as how to identify the most eﬀective target molecules among numerous candidates, and how to comprehensively predict the adverse drug reactions in humans.
Endowed Laboratory of Drug Lifetime Managementhttp://www.f.u-tokyo.ac.jp/~druginfo/index.html
Visiting Prof. Y. Sawada
Assoc. Prof. S. Hori
Assoc. Prof. H.Satoh
Drug lifetime managementResearch Topics
- Development and practice of methodologies for the collection, evaluation, analysis, and distribution of drug information
- Speciﬁcation, standardization, and digitization of drug information, and their applications
- Quantitative prediction of the eﬀects of biodisturbance factors on pharmacokinetics and drug eﬀects
- Quantitative analysis of transplacental transfer of drugs and prediction of fetal toxicity
Our university’s Faculty of Pharmaceutical Sciences bears the social mission of promoting drug discovery and the proper use and evolution of drugs while improving the quality of drug therapies. To these ends, this course in Drug Informatics pursues various research to ensure that the developed drugs can amply exhibit their eﬀects and lead a substantial "drug life." This is what we call "drug lifetime management."
The research topics of this course are that (1) the proper collection of drug information (DI), (2) evaluation/analysis based in pharmacokinetics and pharmacodynamics, (3) quantitative prediction of changes in pharmacokinetics and drug eﬀect due to various risk factors, (4) optimal specification/standardization/digitization, and (5) the proper provision of DI to the actual scene of medical treatment. Concretely speaking, the content of our research is broad-ranging, extending from the creating new DI through in vitro experiments and clinical studies, to the construction of computer systems that support drug therapy, and research on development of systems for analyzing, sharing, and utilizing various kinds of DI (including events related with drug therapies) from the clinical ﬁeld.
Laboratory of Pharmaceutical Regulatory Sciencehttp://www.f.u-tokyo.ac.jp/~regsci/eindex.html
Visiting Prof. Y. Fujiwara
Assoc. Prof. S. Ono
Lecturer T. Yamamoto
Establishing scientiﬁc drug evaluationResearch Topics
- Economic and regulatory impact on global pharmaceutical R&D activities
- Regulatory review and approval of new drugs
- Roles of 'ethnic diﬀerences' in decisions of drug development
- Drug safety and regulatory environments
The goal of our research is to establish scientiﬁc principles and methods in drug evaluation with societal perspectives in mind. Pharmaceutical research and development (R&D), clinical development in particular, regulatory review and approval of new drugs, and post marketing activities are our research interests. We provide evidence on R&D eﬃciency, performance and outcomes of regulations, and public health impact through rigorous analysis based on economic models. Conﬂicts in global pharmaceutical R&D, including recent launch delay of new drugs in Japan and so-called ethnic diﬀerences, are always high on our agenda. Aside from the research activities, we also make efforts to develop human resources in both private and public sectors with up-to-date knowledge, ethics, and philosophy, and rationale in drug evaluation. We oﬀer lectures for graduate and undergraduate students, and a half-year training course for industry and regulatory professionals. We aim to secure transparency and social responsibility on drug regulation through our research and educational programs.
Endowed Laboratory of Drug Policy and Managementhttp://www.f.u-tokyo.ac.jp/~utdpm/
Visiting Prof. K. Tsutani
Assoc. Prof. A. Igarashi
With the goal of rational use of medical resources, we open up a new domain of scholarship merging natural and social sciencesResearch Topics
- Generic drugs and policy development for their rational use
- Pharmacoeconomic analysis of expensive drugs, like biologics
- Individualized treatment through pharmacogenetics
- Analysis of the present status of complementary and alternative medicine (CAM), and research into its safety, eﬃcacy, and economy
- Elimination of the pharmaceutical gap
Medical expenses are growing by the year, and present health-insurance system is at a crossroads. In order to utilize pharmaceuticals appropriately within a limited budget (what we call the "rational use of pharmaceuticals"), we have to evaluate eﬃciencies of various drugs. When we evaluate efficiency, we need to measure both clinical evidence, which endpoints are eﬃcacy and safety, and economic evidence, of which the primary index is economy. In this course, we carry out economic evaluations of drugs that are either under development or already marketed (drugs for rheumatoid arthritis, cancer, smoking cessation therapy, hypertension, etc.)
It is important for us to set various perspectives, including regulatory administration, corporations, medical institutions, and patients, when we take economic evaluations. In this course, from societal perspective that includes all of above-mentioned perspectives, we explore the appropriate role of pharmaceuticals in health services.
After researching methodologies for evaluating them, conducting actual analyses, and analyzing policy, etc., we endeavor to recycle our ﬁndings back into society through policy proposals and the like.
Linked site providing a source of foreign drug price data:Global atlas of drug prices URL: http://dprice.umin.jp/
Endowed Laboratory of Pharmaco-Business Innovationhttp://www.f.u-tokyo.ac.jp/~pbi/english/index.html
Prof. K. Imamura
Visiting Prof. H. Kimura
Assoc. Prof. E. Shimizu
Developing a professional who Understand Both Life Sciences and BusinessResearch Topics
- Studies on industry dynamics in pharmaceutical/life science domain: Analysis of factors driving the reorganization of the industry
- Studies on strategy and management issues in pharmaceutical/life science domain: Finding solutions for management issues of companies, universities, and medical institutions
- Studies on industrial policy in pharmaceutical/life science domain: Making recommendations on social infrastructure for the development of the industry
While Japan aims at sustainable development for the future as a world leader in science and technology, pharmaceutical/life science domain occupies an important position in the national strategy. On the other hand, in a globalizing pharmaceutical industry, the presence of Japan as a market has relatively been declining little by little.
Under such circumstances, the objective of PBI course is to contribute to a sustainable development of the Japanese pharmaceutical industry by 1) conducting multilateral research on managerial issues of rapidly evolving pharmaceutical/life science industry for its long-term growth, such as those related to innovation, public health, global competition and harmonization, 2) fostering a new generation of industrial leaders capable of taking advantages of the new opportunities that are being created, and 3) developing a social infrastructure for drug discoveries including regulations.
Figure: Basic concept of PBI
A lecture from the PBI Seminar
Endowed Laboratory of Human Cell-based Drug DiscoveryProf. Y. Sekino
Visiting Prof. K. Sawada